Takedova dohoda o objevování léků pomocí AI s Iambic za 1,7 miliardy dolarů: co je obsahem paktu
Takeda signed a multi-year drug discovery partnership with private firm Iambic, with milestone payments potentially exceeding $1.7 billion plus royalties. The collaboration will focus on small-molecule programs targeting oncology, gastrointestinal, and inflammatory diseases. Takeda will access Iambic’s NeuralPLexer AI model to predict drug-target binding.